Search Results

Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the radioligand space with a $110 million licensing deal with Orano Med and Texas biotech RadioMedix.

Sanofi’s Orano Med-partnered radioligand therapy AlphaMedix achieved all primary efficacy endpoints, which included a measure of overall response rate, in the mid-stage ALPHAMEDIX-02 study.

Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channel

Orano Med SAS, “Orano Med”, a biotechnology company developing Lead-212 Targeted Alpha Therapy against cancer, and Orbit Discovery Ltd, “Orbit”, a leader in the discovery of therapeutic peptide hits, announced that they have entered into a collaboration to discover specific Peptide Receptor Radionuclide Therapies against cancer cells and advance the development of novel radiopharmaceuticals.

RadioMedix, Inc. and Orano Med announced that the United States Food and Drug Administration has granted Breakthrough Therapy Designation to AlphaMedixTM for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumors who are naïve to peptide receptor radionuclide therapy.

Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results.